As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Luring Big Pharma with GPCR Work, Sosei Heptares Treads Its Own Path to Pursue Small Molecule Targets
September 18, 2019
-
BUSINESS Japan Still in Transition towards Comprehensive Genomic Profiling, Health Coverage Would Expand: Chugai Official
September 17, 2019
-
REGULATORY Show Us Concrete Proposals for Drug Pricing Reform: Kyokai Kenpo Director to Pharma
September 13, 2019
-
REGULATORY Both Payer, Doctor Members Want to Expand Comparator PMP Removal Rule, but Mixed on Timing: Chuikyo
September 12, 2019
-
INTERVIEW Pharma Industry Watered Down Original Proposals for Pricing Overhaul, Corrections Necessary: Kenporen Director
September 12, 2019
-
REGULATORY Katsunobu Kato Makes Comeback as Health Minister
September 11, 2019
-
BUSINESS Vital-Net Carving Out New Businesses in Regenerative Medicine, Robotics
September 11, 2019
-
REGULATORY MOF Budget Examiner Sounds Alarm on “Protected” Market, Prods Speedy Transformation
September 10, 2019
-
BUSINESS Daiichi Sankyo’s Big-Seller Hopeful DS-8201 Filed in Japan
September 10, 2019
-
BUSINESS To Counter Latuda Patent Cliff, Sumitomo Dainippon Poised to Buy 5 “Vants” Companies from Roivant
September 9, 2019
-
BUSINESS Labor Union Urges MSD Japan to Make Convincing Case on Job Cuts
September 6, 2019
-
REGULATORY In Fight against AMR, Japan Set to Forge Prefectural Networks to Push Proper Antibiotic Use
September 5, 2019
-
BUSINESS Roche/Chugai’s Rozlytrek, AstraZeneca COPD Combos and More Hit Shelves
September 5, 2019
-
BUSINESS Keytruda Boon Aside, MSD Japan Mulls Job Cuts for Sales and Marketing
September 4, 2019
-
BUSINESS Astellas Grabs Global Rights to RIKEN’s aAVC Technology in Oncology
September 3, 2019
-
BUSINESS Astellas Revving Up Digital Transformation Drive, Expands Scope of Data to Derive Values
September 2, 2019
-
TRENDS Sales per Drug Rep Hits Record High in FY2018 as Downsizing Speeds Up
August 30, 2019
-
REGULATORY MHLW Panel Puts a Hold on Possible World’s 1st OK for Ono’s Cancer Cachexia Drug
August 30, 2019
-
ORGANIZATION Japan Doctors’ Group Raps Payer Proposal to Scrap Coverage for Pollen Allergy Drugs
August 29, 2019
-
REGULATORY Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
August 28, 2019
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…